Mark Hermanson

Abacus Medicine

Abacus Medicine buys and sells original, prescription medicine across borders. Our business model is based on the core principle of the free movement of goods in the EU's single market. We pursue an ambitious, international growth strategy. We supply a large and growing number of pharmaceuticals to customers in many different markets and have a strategic focus and a strong position in the most expensive types of medicines, such as chemotherapies for cancer treatment or immunosuppressive drugs used in connection with organ transplants. Our ability to deliver on this strategy is rooted in our strong sourcing network and industry leading capabilities in complex data analysis. Our proven growth platform in Parallel Trade can be leveraged in two related, global industries: Supply for Clinical Trials and Unlicensed Medicines. Our early phase initiatives in these two market segments are conducted under the brand name Abacus Medicine Pharma Services. Established in 2004 by CEO Flemming Wagner and Medical Director John Wagner, Abacus Medicine has experienced significant growth ever since. Today, we are more than 1,300 colleagues in Europe and beyond.